The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor
Abstract
Pulmonary fibrosis is characterized by chronic scar formation and deposition of extracellular matrix, resulting in impaired lung function and respiratory failure. Idiopathic pulmonary fibrosis (IPF) is associated with pronounced morbidity and mortality and responds poorly to known therapeutic interventions; there are no known drugs that effectively block or reverse progressive fibrosis. Transforming growth factor beta (TGF-beta) is known to mediate extracellular matrix gene regulation and appears to be a major player in both the initiation and progression of IPF. TGF-beta mediates its biological effects through members of a family of activin receptor-like kinases (ALK). We have used a gene transfer model of progressive TGF-beta1-induced pulmonary fibrosis in rats to study a newly described orally active small molecular weight drug that is a potent and selective inhibitor of the kinase activity of ALK5, the specific TGF-beta receptor. We show that the drug inhibits the induction of fibrosis when administered at the time of initiation of fibrogenesis and, most important, blocks progressive fibrosis when administered transiently to animals with established fibrosis. These data show promise of the development of an effective therapeutic intervention for IPF and that inhibition of chronic progressive fibrosis may be achieved by blocking TGF-beta receptor activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Determination of hydroxyproline
Stegemann, H., & Stalder, K. (1967) · Clinica Chimica Acta · doi:10.1016/0009-8981(67)90167-2 · Cited by 1,570
Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors
Goumans, M.-J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1743 · Cited by 1,123
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Self-citationKolb, M., Margetts, P. J., Anthony, D. C., Pitossi, F., & Gauldie, J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12568 · Cited by 753
Self-citationBett, A. J., Haddara, W., Prevec, L., & Graham, F. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8802 · Cited by 744
TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target?
Martin, M., Lefaix, J.-L., & Delanian, S. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00435-1 · Cited by 657
Idiopathic Pulmonary Fibrosis: Relationship between Histopathologic Features and Mortality
KING, T. E., SCHWARZ, M. I., BROWN, K., TOOZE, J. A., COLBY, T. V., WALDRON, J. A., FLINT, A., THURLBECK, W., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 628
Cited by
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011) · Growth Factors · doi:10.3109/08977194.2011.595714 · Cited by 1,161
Fibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
Oxidative stress and glutathione in TGF-β-mediated fibrogenesis
Liu, R.-M., & Gaston Pravia, K. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.026 · Cited by 469
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Metadata
- Authors
- Bonniaud, P., Margetts, P. J., Kolb, M., Schroeder, J. A., Kapoun, A. M., Damm, D., Murphy, A., Chakravarty, S., Dugar, S., Higgins, L., Protter, A. A., & Gauldie, J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-15
- Volume
- 171
- Issue
- 8
- Pages
- 889-898
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2136592357
- Cited by
- 256
- References
- 42
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. https://app.cochat.ai/papers/10.1164/rccm.200405-612oc
- The paper
- Bonniaud, P., Margetts, P. J., Kolb, M., Schroeder, J. A., Kapoun, A. M., Damm, D., Murphy, A., Chakravarty, S., Dugar, S., Higgins, L., Protter, A. A., & Gauldie, J. (2005). Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200405-612oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
